This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n9http://linked.opendata.cz/resource/drugbank/drug/DB00464/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00464/identifier/drugbank/
n17http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00464/identifier/national-drug-code-directory/
n23http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00464/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00464/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://www.drugs.com/cdi/
n7http://www.rxlist.com/cgi/generic2/
n5http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00464/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00464
rdf:type
n3:Drug
n3:description
An anionic surface-active agent used for its wetting properties in industry and used in medicine as an irritant and sclerosing agent for hemorrhoids and varicose veins.
n3:dosage
n21:271B5674-363D-11E5-9242-09173F13E4C5 n21:271B5675-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.
n3:manufacturer
n4:271B566F-363D-11E5-9242-09173F13E4C5 n4:271B566E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n19:DB00464 n23:DB00464
dcterms:title
Sodium Tetradecyl Sulfate
adms:identifier
n9:46505919 n12:5248 n13:67457-162-02 n14:5058 n15:DB00464 n20:PA164746759
n3:mechanismOfAction
Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.
n3:packager
n4:271B566D-363D-11E5-9242-09173F13E4C5 n4:271B566C-363D-11E5-9242-09173F13E4C5
n3:synonym
Tetradecyl sodium sulfate STS
n3:toxicity
LD<sub>50</sub>=1250 mg/kg (Orally in rat); LD<sub>50</sub>=3 ml/kg (Skin in rat)
n16:hasAHFSCode
n17:24-16-00
n24:hasConcept
n25:M0020118
foaf:page
n7:sotradecol.htm n11:sodium-tetradecyl-sulfate.html
n3:IUPAC-Name
n5:271B567A-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5680-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B567F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B567C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B567D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B567E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B5678-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B5676-363D-11E5-9242-09173F13E4C5 n5:271B5679-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B5677-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n22:C05BB04
n3:H-Bond-Acceptor-Count
n5:271B5686-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B5687-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5681-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5682-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5684-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5683-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B5685-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
1191-50-0
n3:category
n3:containedIn
n10:271B5672-363D-11E5-9242-09173F13E4C5 n10:271B5673-363D-11E5-9242-09173F13E4C5 n10:271B5670-363D-11E5-9242-09173F13E4C5 n10:271B5671-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B568B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B568D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B568E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B568A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B5689-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B568C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B567B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B5688-363D-11E5-9242-09173F13E4C5